Fisher & Paykel Healthcare Corporation Limited

The Business

Fisher & Paykel Healthcare makes humidification and respiratory devices, split between a Hospital division (nasal high flow therapy and invasive ventilation support, roughly two-thirds of group revenue) and a Homecare division (obstructive sleep apnoea and chronic respiratory care). The model is razor-and-blade: hospitals install the hardware once, then repurchase disposable consumables for years afterward. That consumables tail, not the hardware sale itself, is what generates the 88% recurring revenue base and makes earnings unusually predictable for a device manufacturer.

Recent Performance

Revenue grew 14.2% in FY26 to NZ$2,308 million, building on 16.0% growth the prior year, so the growth is not decelerating off an unusually weak base. Hospital consumables grew 14% in constant currency even through a subdued respiratory illness season, evidence that adoption is now a structural clinical practice shift rather than a seasonal flu-driven spike. The market has rewarded this consistency with a rich re-rating, and the stock now trades at the top of its peer set on both earnings and EBITDA multiples.

Outlook

Growth is expected to decelerate over the next few years as the hardware installation cycle normalises, though consumables revenue should continue compounding at a steadier pace off the growing installed base. Gross margin is expected to keep expanding, driven by a continuous improvement programme in manufacturing rather than pricing gains, a structural driver rather than a one-off. Margin expansion is expected to continue over the medium term before eventual competitive entry and patent expiry compress margins back toward historical norms over the following decade.

Key Risks

The dominant risk sits with valuation rather than operations: at current multiples, there is very little room for disappointment, and any shortfall in growth, margin or the discount rate environment would have an outsized effect on the share price relative to a more moderately priced peer. On the operational side, a slowdown in new clinical guideline publication or a tightening of hospital capital budgets could stall the core growth engine that has driven the recent re-rating. A longer-dated risk is entry into nasal high flow therapy by a larger competitor such as Medtronic or Philips, which could compress both market share and gross margin, though this would likely play out over several years rather than suddenly given the clinical evidence burden any new entrant would face.

What to Watch

The thesis-defining event over the next 12-24 months is the Reserve Bank of Australia's rate cycle, which will confirm whether elevated discount rates persist or begin normalising toward levels the market appears to already be assuming in its pricing of long-duration growth assets like this one.

• 12-24 months RBA rate cut initiating discount rate normalisation. A shift lower in rates would ease pressure on richly-valued long-duration growth names generally, this one included.
• 12-18 months New nasal high flow clinical guideline publication in anaesthesia or COPD, which would extend the addressable market and reinforce the clinical evidence moat.

Company Description

Fisher & Paykel Healthcare operates two divisions. Hospital, contributing roughly two-thirds of group revenue, sells nasal high flow therapy systems and humidification equipment for invasive and non-invasive ventilation in intensive care and general wards. Homecare, the remainder, sells continuous positive airway pressure devices and masks for obstructive sleep apnoea, competing directly with ResMed. Manufacturing spans New Zealand, Mexico, and an expanding China facility, providing some geographic insulation against any single country's trade policy. Revenue is split roughly 88% recurring consumables and 12% capital hardware.

Where the Growth Is

Nasal high flow therapy is the single most important growth driver, contributing an estimated 65-68% of group revenue. Growth is currently running near 13% in constant currency, and we expect this to decelerate materially over the coming decade as the therapy matures and comparisons get tougher. Each new clinical practice guideline that references nasal high flow (twelve exist today, with three or more expected in the next two years) meaningfully expands the addressable market by embedding the therapy further into standard hospital protocol.

Competitive Position

The company's advantage does not rest primarily on patents, which typically run for a decade before expiry. It rests on a clinical evidence base of more than 4,500 published studies underpinning twelve practice guidelines. Once a therapy is written into a clinical guideline, hospitals adopt it as protocol, and switching away from an established supplier requires re-proving efficacy from scratch, a cost most institutions won't bear. This creates switching costs that persist even after any individual patent lapses, and the evidence base compounds with each new study published, arguably widening the advantage over time rather than eroding it. We see this durability lasting roughly 7-10 years before larger competitors can plausibly contest it.

Management & Capital Discipline

Capital allocation has been disciplined: roughly 10% of revenue reinvested into research and development, a 65% dividend payout ratio, and organic capacity expansion (including a new manufacturing facility) funded from operating cash flow rather than debt. There has been no value-destructive acquisition in the past five years. The chief executive's 43-year tenure with the company provides continuity and a credible track record, but there is no publicly disclosed succession plan, an underappreciated key-person risk given how central that tenure has been to the culture and execution record.

Financial Position

The balance sheet carries net cash rather than net debt, and interest coverage is not a meaningful constraint given the company's near-zero leverage. Operating cash flow of NZ$661 million in FY26 comfortably funds both the dividend and the growth capital expenditure programme, with free cash flow of NZ$466 million after NZ$195 million of capex. This is a company that could weather a prolonged downturn in demand without any financing stress.